+ 1-971-202-1575 , TollFree:+ 1-800-910-6452
  [email protected]
Global Ophthalmic Drugs Market (Treatment, Type, Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Opportunities, Segmentation, Forecast 2013-2020
  • |
  • Published By : Allied Market Research

Report Overview

Ophthalmic drugs are the drugs that are used for the treatment of eye diseases and disorders. The ophthalmic drugs market is growing due to increase in prevalence of eye disorders and the use of combination therapies. Combination therapies have various advantages over traditional medication such as improved patient compliance and efficacy. 

The drivers that support the growth of ophthalmic drug market are aging population, changing lifestyle, technological changes, and increase in healthcare spending. Lack of awareness among people regarding eye diseases and disorders, absence of health insurance in developing countries are some of the challenges faced by the ophthalmic drugs market.

Ophthalmic drug Market analysis by Treatment:

The market is segmented into Dry eye drugs, Retinal drugs, Anti-inflammatory/allergy/infective drugs, Anti-glaucoma drugs. Glaucoma has the largest market share in the ophthalmic drugs market.

Ophthalmic drug Market analysis by Type

Ophthalmic drug type market is segmented into Prescription drugs and OTC drugs.OTC drugs for ocular allergy and dry eye is rapidly growing.

Ophthalmic drug Market analysis by geography

Geographically, ophthalmic drug market is segmented into North America (US), Europe (Germany, UK, and France), Asia Pacific (Japan, India, and China), and LAMEA. North America has the largest ophthalmic drugs market. Asia is the fastest growing ophthalmic drugs market.

Competitive landscape

Key players in the market focus on product launch, research & new product development, and mergers & acquisition. Product launch, with new combination therapies is the most important strategy adopted by major players in market. Novartis (ALCON), Allergan, Santen, Pfizer, Merck and Roche are the major players in the global ophthalmic drugs market. ALCON launched ILEVRO Suspension used to reduce pain and inflammation resulting from cataract surgery.

High Level Analysis

Porter’s five forces model reveals that bargaining power of supplier is less due to low switching cost and bargaining power of buyers is high due to availability of substitute products. Threat of substitute is high due to similarity in therapeutic functioning. Business strategies adopted by key players are analyzed. SWOT analysis helps in understanding the internal and external factors required for strategic business planning. 


This report analyses the factors that are driving and limiting the growth of the market
Market estimations are done according to the market trends for the period 2013-2018
Analysis of key strategies adopted by market players would assist in providing in-depth understanding of the market intelligence
In-depth analysis of segments such as targeted drug, type, and geography provides insights that would allow companies to gain competitive edge
Emphasis is laid on key factors affecting the growth of global ophthalmic drugs market. These factors are critically analyzed to reveal the most influencing factors in ophthalmic drugs market


The Ophthalmic drugs market is segmented based on Targeted drugs, Types and geography.


  • Dry eye Drugs
  • Retinal Drugs
  • Anti-inflammatory/Allergy/Infective Drugs
  • Anti-Glaucoma Drugs


  • Prescription Drugs
  • OTC Drugs


  • 1.North America 
    • U.S.
  • 2.Europe
    • Germany
    • UK
    • France
  • 3.Asia Pacific
    • Japan
    • India
    • China
  • 4.LAMEA

Similar Market Studies



Reports and Intelligence

We Accept

  • Stay Connected

Copyright ©2018 Reportsandintelligence All Rights Reserved